189
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine

, , , , , , , , , , , & show all
Pages 979-982 | Received 18 Sep 2019, Accepted 23 Nov 2019, Published online: 04 Dec 2019
 

Disclosure statement

Authors declared no conflicts of interest.

Authorship contributions

GF: designed the research study, performed the research, analyzed the data, wrote the paper; EF: performed the research, wrote the paper; TO: performed the research, analyzed the data, wrote the paper; AP: analyzed the data; SL: performed the research, analyzed the data; MC, LF, CG, MP, AP, RP enrolled patients; FLC: designed the research study, enrolled patients; MTV: designed the research study, enrolled patients and wrote the paper. All authors critically reviewed and approved the final version of the manuscript.

Additional information

Funding

This study was supported by Associazione Italiana Ricerca sul Cancro (AIRC, IG N.16952 to MTV), by Società Italiana Ematologia Sperimentale, SIES (to GF), by an unrestricted Research Grant from Celgene and by AIRC 5 × 1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture Airc). A detailed description of the MYNERVA project is available at http://www.progettoagimm.it.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.